



PRESS RELEASE

Scientific validation of Ziwig Endotest® as a diagnostic tool for endometriosis by an article in the NEJM Evidence - New England Journal of Medicine

Lyon, 12th June 2023 – Ziwig, a French biotech and precursor in salivary RNA analysis, is proud to announce that Ziwig Endotest® has been validated as a diagnostic tool for endometriosis, according to a study published in the prestigious scientific journal NEJM Evidence - New England Journal of Medicine on 9th June, 2023 [DOI:10.1056/EVIDoa2200282](https://doi.org/10.1056/EVIDoa2200282)

The results published confirm the performance and reproducibility of Ziwig Endotest®, with sensitivity and specificity of over 95%, making it the only non-invasive diagnostic tool of unquestionable effectiveness and an alternative to surgery. This is *"a revolution in diagnosis, with tremendous prospects for patients"*, said Prof. Horace Roman, founder of IfemEndo Bordeaux.

In addition, this study's demonstration of the effectiveness of the combination of Next Generation Sequencing (NGS) and Artificial Intelligence (AI) heralds the imminent advent of new non-invasive tools for predicting response to treatment, defining the different biological phenotypes of the disease, and improving the efficiency of diagnostic triage by imaging.

"Early diagnosis of endometriosis enables this cause of infertility to be identified and treatment to be adapted quickly" underlines Prof. Samir Hamamah, author of the first French report on the causes of infertility¹, Head of the Reproductive Biology Department at Montpellier University Hospital.

Ziwig Endotest® is currently available in Switzerland, the United Kingdom, Italy, Germany, Sweden, Norway, Denmark, Iceland, Lithuania, Latvia, Estonia, Saudi Arabia, and the United Arab Emirates. It will shortly be available in Hungary, Belgium, Luxembourg, Kuwait, Qatar, and Israel. It is reimbursed in Switzerland.

In France, Ziwig is working closely with the health authorities to make Ziwig Endotest® available to healthcare professionals and patients before the end of 2023.

"It's about time that a revolutionary, easy-to-use tool is finally available to the millions of women suffering from endometriosis (...) to help them preserve their fertility and quality of life." says Priscilla Saracco, Endomind Expert Patient.

¹ *Rapport sur les causes d'infertilité - Vers une stratégie nationale de lutte contre l'infertilité*, Pr. Samir Hamamah et Madame Salomé Berlioux, 21.02.2022.

About Ziwig

Ziwig is an innovative French biotech specialising in salivary RNA analysis and AI. It operates as an ecosystem at the crossroads of several medical, scientific, and digital disciplines. Ziwig is strongly committed to disruptive innovations that support the transformation of healthcare systems towards more effective, more humane, and more accessible precision medicine.

About Ziwig Endotest®

Ziwig Endotest® is the first saliva-based diagnostic test for endometriosis. It provides a reliable and robust diagnosis of the disease within 7 days, based on a simple saliva sample taken anywhere in the territory. The biological examination is carried out in a specialised, fully automated central laboratory.

Reference to the NEJM Evidence - New England Journal of Medicine article:

[DOI: 10.1056/EVIDoa2200282](https://doi.org/10.1056/EVIDoa2200282)

PRESS CONTACT

Véronique Simon-Cluzel, – Finn Partners, Mobile : +33 (0)6 68 86 32 30

Aurélia Adloff, - Finn Partners, Mobile: +333 (0)6 89 38 94 70

sante@finnpartners.com